| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8592397 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months from now) | |
| US9457036 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months from now) | |
| US9744181 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months from now) | |
| US8716264 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months from now) | |
Truvada is owned by Gilead.
Truvada contains Emtricitabine; Tenofovir Disoproxil Fumarate.
Truvada has a total of 4 drug patents out of which 0 drug patents have expired.
Truvada was authorised for market use on 02 August, 2004.
Truvada is available in tablet;oral dosage forms.
Truvada can be used as treatment of hiv infection, treatment of hiv; method of treatment of adults infected with hiv-1; treatment of hiv-1 infection in pediatric patients 12 years of age and older.
The generics of Truvada are possible to be released after 13 January, 2024.
Drugs and Companies using EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient
Market Authorisation Date: 02 August, 2004
Treatment: Treatment of hiv; Method of treatment of adults infected with hiv-1; Treatment of hiv-1 infection in pediatric patients 12 years of age and older; Treatment of hiv infection
Dosage: TABLET;ORAL
TRUVADA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic